View Cart  

FDA Reviewer Supports Cardiokine Low-Sodium Drug for One of Two Proposed Indications

A A
Cardiokine’s lixivaptan should be approved to treat low sodium levels associated with syndrome of inappropriate antidiuretic hormone (SIADH), an FDA reviewer says.

To View This Article:

Login

Subscribe To Drug Industry Daily